$ANIP
ANI Pharmaceuticals Inc Stock $anip

$anip Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-K Financial Statement

#000114420419010541 Filed on February 27, 2019

Income Statement

Concept	2018 Q4	2018 Q3	2018 Q2
Revenue	$57.12M	$50.70M	$47.27M
YoY Change	20.8%	5.27%	5.59%
Cost Of Revenue	$20.13M	$15.61M	$16.59M
YoY Change	-1.56%	-25.97%	-21.44%
Gross Profit	$36.99M	$35.10M	$30.68M
YoY Change	37.82%	29.58%	29.75%
Gross Profit Margin	64.76%	69.22%	64.9%
Selling, General & Admin	$13.38M	$11.77M	$9.962M
YoY Change	50.51%	46.71%	34.99%
% of Gross Profit	36.17%	33.53%	32.48%
Research & Development	$3.480M	$4.667M	$5.137M
YoY Change	31.32%	77.18%	137.06%
% of Gross Profit	9.41%	13.3%	16.75%
Depreciation & Amortization	$8.680M	$8.548M	$8.313M
YoY Change	23.65%	20.41%	17.07%
% of Gross Profit	23.47%	24.35%	27.1%
Operating Expenses	$25.55M	$16.44M	$15.10M
YoY Change	37.66%	54.24%	58.15%
Operating Profit	$11.45M	$10.11M	$7.263M
YoY Change	55.1%	8.39%	3.85%
Interest Expense	-$3.630M	-$3.768M	-$3.730M
YoY Change	19.8%	23.46%	23.31%
% of Operating Profit	-31.72%	-37.26%	-51.36%
Other Income/Expense, Net	-$480.0K	$20.00K	-$30.00K
YoY Change		-78.95%	57.89%
Pretax Income	$7.340M	$6.366M	$3.503M
YoY Change	68.74%	-0.13%	-11.32%
Income Tax	-$1.910M	-$1.329M	-$726.0K
% Of Pretax Income	-26.02%	-20.88%	-20.73%
Net Earnings	$5.430M	$5.037M	$2.777M
YoY Change	-156.39%	6.72%	3.58%
Net Earnings / Revenue	9.51%	9.93%	5.88%
Basic Earnings Per Share	$0.46	$0.43	$0.24
Diluted Earnings Per Share	$0.46	$0.42	$0.23
COMMON SHARES
Basic Shares Outstanding		11.71M shares	11.68M shares
Diluted Shares Outstanding		11.80M shares	11.79M shares

Balance Sheet

Concept	2018 Q4	2018 Q3	2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$43.00M	$44.10M	$55.00M
YoY Change	38.26%	145.0%	554.76%
Cash & Equivalents	$43.01M	$44.14M	$54.99M
Short-Term Investments
Other Short-Term Assets	$4.500M	$5.000M	$1.800M
YoY Change	60.71%	4.17%	-33.33%
Inventory	$40.50M	$40.01M	$37.76M
Prepaid Expenses	$4.524M	$5.004M	$1.768M
Receivables	$64.84M	$67.65M	$56.12M
Other Receivables	$0.00	$0.00	$1.700M
Total Short-Term Assets	$152.9M	$156.8M	$152.4M
YoY Change	16.16%	24.84%	35.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$38.09M	$37.42M	$22.84M
YoY Change	86.69%	115.05%	52.63%
Goodwill	$3.580M	$2.342M	$1.838M
YoY Change	94.78%		0.0%
Intangibles	$201.6M	$209.5M	$217.5M
YoY Change	-12.27%		10.61%
Long-Term Investments
YoY Change
Other Assets	$1.468M	$1.412M	$1.049M
YoY Change	77.08%	-96.06%	-96.81%
Total Long-Term Assets	$277.7M	$282.7M	$271.8M
YoY Change	-1.0%	15.41%	10.33%
TOTAL ASSETS
Total Short-Term Assets	$152.9M	$156.8M	$152.4M
Total Long-Term Assets	$277.7M	$282.7M	$271.8M
Total Assets	$430.6M	$439.4M	$424.2M
YoY Change	4.48%	18.61%	18.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.884M	$7.257M	$7.949M
YoY Change	144.74%	25.12%	152.11%
Accrued Expenses	$1.707M	$2.818M	$1.863M
YoY Change	8.66%	-87.31%	19.04%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$3.256M	$5.692M	$5.217M
YoY Change	-2.89%
Total Short-Term Liabilities	$165.5M	$46.90M	$39.68M
YoY Change	322.02%	28.85%	40.24%
LONG-TERM LIABILITIES
Long-Term Debt	$67.30M	$65.95M	$67.26M
YoY Change	-3.79%	-56.41%	-56.44%
Other Long-Term Liabilities	$496.0K
YoY Change
Total Long-Term Liabilities	$67.79M	$65.95M	$67.26M
YoY Change	-3.08%	-56.41%	-56.44%
TOTAL LIABILITIES
Total Short-Term Liabilities	$165.5M	$46.90M	$39.68M
Total Long-Term Liabilities	$67.79M	$65.95M	$67.26M
Total Liabilities	$233.3M	$247.0M	$239.1M
YoY Change	-1.7%	31.58%	30.87%
SHAREHOLDERS EQUITY
Retained Earnings	$11.49M	$6.058M	$1.021M
YoY Change	-386.77%		13.07%
Common Stock	$1.000K	$1.000K	$1.000K
YoY Change	0.0%		0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$197.3M	$192.5M	$185.1M
YoY Change
Total Liabilities & Shareholders Equity	$430.6M	$439.4M	$424.2M
YoY Change	4.48%	18.61%	18.08%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2018 Q2
OPERATING ACTIVITIES
Net Income	$5.430M	$5.037M	$2.777M
YoY Change	-156.39%	6.72%	3.58%
Depreciation, Depletion And Amortization	$8.680M	$8.548M	$8.313M
YoY Change	23.65%	20.41%	17.07%
Cash From Operating Activities	$27.23M	$8.320M	$8.590M
YoY Change	72.23%	-51.29%
INVESTING ACTIVITIES
Capital Expenditures	-$1.000M	-$1.380M	-$1.080M
YoY Change	-71.01%	-44.35%	-53.04%
Acquisitions
YoY Change
Other Investing Activities	$600.0K	-$17.07M	-$5.170M
YoY Change	-101.29%
Cash From Investing Activities	-$410.0K	-$18.44M	-$6.250M
YoY Change	-99.18%	643.55%	170.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-27.95M	-730.0K	690.0K
YoY Change	-158.93%	-85.22%	-531.25%
NET CHANGE
Cash From Operating Activities	27.23M	8.320M	8.590M
Cash From Investing Activities	-410.0K	-18.44M	-6.250M
Cash From Financing Activities	-27.95M	-730.0K	690.0K
Net Change In Cash	-1.130M	-10.85M	3.030M
YoY Change	-108.61%	-212.32%	-222.67%
FREE CASH FLOW
Cash From Operating Activities	$27.23M	$8.320M	$8.590M
Capital Expenditures	-$1.000M	-$1.380M	-$1.080M
Free Cash Flow	$28.23M	$9.700M	$9.670M
YoY Change	46.57%	-50.41%	320.43%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2018	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2018	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	58788000
CY2018Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	47705000
CY2017Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	34686000
CY2018Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2018	dei	Document Type DocumentType	10-K
CY2018	dei	Amendment Flag AmendmentFlag	false
CY2018	dei	Document Period End Date DocumentPeriodEndDate	2018-12-31
CY2018	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
CY2018	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2018	dei	Entity Registrant Name EntityRegistrantName	ANI PHARMACEUTICALS INC
CY2018	dei	Entity Central Index Key EntityCentralIndexKey	0001023024
CY2018	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2018Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	1000
CY2018Q4	anip	Class C Special Stock Value ClassCSpecialStockValue	0
CY2018	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2018	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
CY2018Q2	dei	Entity Public Float EntityPublicFloat	609300000
CY2018	dei	Trading Symbol TradingSymbol	ANIP
CY2018	dei	Entity Shell Company EntityShellCompany	false
CY2018	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2018	dei	Entity Small Business EntitySmallBusiness	false
CY2018Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	43008000
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31144000
CY2018Q4	us-gaap	Inventory Net InventoryNet	40503000
CY2017Q4	us-gaap	Inventory Net InventoryNet	37727000
CY2018Q4	us-gaap	Prepaid Taxes PrepaidTaxes	0
CY2017Q4	us-gaap	Prepaid Taxes PrepaidTaxes	1162000
CY2018Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	4524000
CY2017Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	2784000
CY2018Q4	us-gaap	Assets Current AssetsCurrent	152877000
CY2017Q4	us-gaap	Assets Current AssetsCurrent	131605000
CY2018Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	38090000
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20403000
CY2018Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	5021000
CY2017Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	5006000
CY2018Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	27964000
CY2017Q4	us-gaap	Deferred Tax Assets Net Noncurrent DeferredTaxAssetsNetNoncurrent	22667000
CY2018Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	201604000
CY2017Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	229790000
CY2018Q4	us-gaap	Goodwill Goodwill	3580000
CY2017Q4	us-gaap	Goodwill Goodwill	1838000
CY2018Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1468000
CY2017Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	829000
CY2018Q4	us-gaap	Assets Assets	430604000
CY2017Q4	us-gaap	Assets Assets	412138000
CY2018Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8884000
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3630000
CY2018Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1707000
CY2017Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1571000
CY2018Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	8456000
CY2017Q4	us-gaap	Accrued Royalties Current AccruedRoyaltiesCurrent	12164000
CY2018Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3524000
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2306000
CY2018Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	5022000
CY2017Q4	us-gaap	Accrued Income Taxes Current AccruedIncomeTaxesCurrent	0
CY2018Q4	anip	Accrued Government Rebates AccruedGovernmentRebates	8974000
CY2017Q4	anip	Accrued Government Rebates AccruedGovernmentRebates	7930000
CY2018Q4	anip	Returned Goods Reserve ReturnedGoodsReserve	12552000
CY2017Q4	anip	Returned Goods Reserve ReturnedGoodsReserve	8274000
CY2018Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	3256000
CY2017Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	3353000
CY2018Q4	us-gaap	Liabilities Current LiabilitiesCurrent	165549000
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	39228000
CY2018Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	67296000
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	69946000
CY2018Q4	us-gaap	Liabilities Liabilities	233341000
CY2017Q4	us-gaap	Liabilities Liabilities	237382000
CY2016	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	6685000
CY2017Q4	anip	Class C Special Stock Value ClassCSpecialStockValue	0
CY2018Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2017Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2018Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	659000
CY2017Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	259000
CY2018Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	186812000
CY2017Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	179020000
CY2018	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	0
CY2017	us-gaap	Costs And Expenses CostsAndExpenses	148513000
CY2016	us-gaap	Costs And Expenses CostsAndExpenses	108543000
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	166217000
CY2018Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2018Q4	us-gaap	Stockholders Equity StockholdersEquity	197263000
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	174756000
CY2018Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	430604000
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	412138000
CY2017	us-gaap	Revenues Revenues	176842000
CY2016	us-gaap	Revenues Revenues	128622000
CY2018	us-gaap	Revenues Revenues	201576000
CY2017	us-gaap	Cost Of Revenue CostOfRevenue	79032000
CY2016	us-gaap	Cost Of Revenue CostOfRevenue	48780000
CY2018	us-gaap	Cost Of Revenue CostOfRevenue	73024000
CY2017	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9070000
CY2016	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2906000
CY2018	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	15388000
CY2017	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	31580000
CY2016	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	27829000
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	44063000
CY2017	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	903000
CY2017	us-gaap	Operating Income Loss OperatingIncomeLoss	28329000
CY2016	us-gaap	Operating Income Loss OperatingIncomeLoss	20079000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	35359000
CY2017	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-12035000
CY2016	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-11327000
CY2018	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-14758000
CY2017	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	55000
CY2016	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-74000
CY2018	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-550000
CY2017	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	16349000
CY2016	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	8678000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	20051000
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17425000
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4744000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4557000
CY2017	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.09
CY2016	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.34
CY2018	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	1.30
CY2018	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6700000
CY2017	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6100000
CY2016	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	6100000
CY2018Q4	us-gaap	Short Term Debt Percentage Bearing Fixed Interest Rate ShortTermDebtPercentageBearingFixedInterestRate	0.030
CY2017	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11547000
CY2016	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11445000
CY2017	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.09
CY2016	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.34
CY2017	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11547000
CY2016	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11573000
CY2017	us-gaap	Interest Costs Capitalized Adjustment InterestCostsCapitalizedAdjustment	554000
CY2018Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1210000
CY2017Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	510000
CY2017	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-1076000
CY2016	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	3934000
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-1076000
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	3913000
CY2017	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1076000
CY2016	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	3913000
CY2018	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	15494000
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	15340000
CY2018	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	15340000
CY2018	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11677000
CY2018	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	1.31
CY2018	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11772000
CY2018	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4400000
CY2017	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4800000
CY2016	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4500000
CY2018	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	7170000
CY2017	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	4313000
CY2016	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	4312000
CY2018	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	7002000
CY2017	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	6720000
CY2016	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	6372000
CY2018	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	1463000
CY2017	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	845000
CY2016	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	844000
CY2018	us-gaap	Interest Costs Capitalized Adjustment InterestCostsCapitalizedAdjustment	724000
CY2016	us-gaap	Interest Costs Capitalized Adjustment InterestCostsCapitalizedAdjustment	234000
CY2018	us-gaap	Interest Expense Debt InterestExpenseDebt	14911000
CY2017	us-gaap	Interest Expense Debt InterestExpenseDebt	11324000
CY2016	us-gaap	Interest Expense Debt InterestExpenseDebt	11294000
CY2016	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6067000
CY2016	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	122000
CY2016Q4	us-gaap	New Accounting Pronouncement Or Change In Accounting Principle Cumulative Effect Of Change On Equity Or Net Assets1 NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1	0
CY2017	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6090000
CY2017	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	259000
CY2016	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	1570000
CY2016	us-gaap	Stock Repurchased And Retired During Period Value StockRepurchasedAndRetiredDuringPeriodValue	2500000
CY2016	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0
CY2016	us-gaap	Adjustments To Additional Paid In Capital Tax Effect From Share Based Compensation AdjustmentsToAdditionalPaidInCapitalTaxEffectFromShareBasedCompensation	617000
CY2017	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	353000
CY2017	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6782000
CY2018	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2978000
CY2018	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0
CY2018Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	27671000
CY2017Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	22139000
CY2018Q4	us-gaap	Retail Related Inventory Packaging And Other Supplies RetailRelatedInventoryPackagingAndOtherSupplies	2563000
CY2017Q4	us-gaap	Retail Related Inventory Packaging And Other Supplies RetailRelatedInventoryPackagingAndOtherSupplies	1527000
CY2017	us-gaap	Depreciation Depreciation	1200000
CY2016	us-gaap	Depreciation Depreciation	900000
CY2018Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	10620000
CY2017Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	13901000
CY2018Q4	us-gaap	Inventory Gross InventoryGross	42064000
CY2017Q4	us-gaap	Inventory Gross InventoryGross	38077000
CY2018Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	1561000
CY2017Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	350000
CY2018Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	46491000
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	26992000
CY2018Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	8401000
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6589000
CY2018	us-gaap	Depreciation Depreciation	2100000
CY2018	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	700000
CY2017	us-gaap	Interest Costs Capitalized InterestCostsCapitalized	600000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	288215000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	86611000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	284716000
CY2017Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	54926000
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	31700000
CY2017	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	26700000
CY2016	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	21400000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	31761000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	31279000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	29833000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	26428000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	26360000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	55943000
CY2018Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	201604000
CY2017	us-gaap	Share Based Compensation ShareBasedCompensation	6090000
CY2016	us-gaap	Share Based Compensation ShareBasedCompensation	6067000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	6782000
CY2017	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	3560000
CY2016	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-8911000
CY2018	us-gaap	Deferred Income Taxes And Tax Credits DeferredIncomeTaxesAndTaxCredits	-5180000
CY2017	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	27928000
CY2016	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	22343000
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	33742000
CY2017	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	7666000
CY2016	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	7281000
CY2018	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	8465000
CY2017	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	12893000
CY2016	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	23963000
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	4743000
CY2017	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-5356000
CY2016	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1938000
CY2018	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	379000
CY2017	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	17000
CY2016	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	647000
CY2018	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	1142000
CY2017	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3000
CY2016	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1076000
CY2018	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	3466000
CY2017	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	-417000
CY2016	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	6269000
CY2018	us-gaap	Increase Decrease In Royalties Payable IncreaseDecreaseInRoyaltiesPayable	-3708000
CY2017	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	-3560000
CY2016	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	3525000
CY2018	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	6184000
CY2017	anip	Increase Decrease Accrued Government Rebates IncreaseDecreaseAccruedGovernmentRebates	2039000
CY2016	anip	Increase Decrease Accrued Government Rebates IncreaseDecreaseAccruedGovernmentRebates	1260000
CY2018	anip	Increase Decrease Accrued Government Rebates IncreaseDecreaseAccruedGovernmentRebates	1044000
CY2017	anip	Increase Decrease In Returned Goods Reserve IncreaseDecreaseInReturnedGoodsReserve	2518000
CY2016	anip	Increase Decrease In Returned Goods Reserve IncreaseDecreaseInReturnedGoodsReserve	3108000
CY2018	anip	Increase Decrease In Returned Goods Reserve IncreaseDecreaseInReturnedGoodsReserve	4278000
CY2017	anip	Increase Decrease Of Accrued Expenses Compensation And Others IncreaseDecreaseOfAccruedExpensesCompensationAndOthers	1319000
CY2016	anip	Increase Decrease Of Accrued Expenses Compensation And Others IncreaseDecreaseOfAccruedExpensesCompensationAndOthers	1383000
CY2018	anip	Increase Decrease Of Accrued Expenses Compensation And Others IncreaseDecreaseOfAccruedExpensesCompensationAndOthers	968000
CY2017	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	39419000
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	27472000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	67074000
CY2017	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	97624000
CY2016	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	144494000
CY2018	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	5169000
CY2017	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	10369000
CY2016	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4566000
CY2018	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5743000
CY2017	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-107993000
CY2016	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-149060000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-27379000
CY2017	anip	Payments Of Debt Issuance Costs And Convertible Debt Repurchase Costs PaymentsOfDebtIssuanceCostsAndConvertibleDebtRepurchaseCosts	2737000
CY2016	anip	Payments Of Debt Issuance Costs And Convertible Debt Repurchase Costs PaymentsOfDebtIssuanceCostsAndConvertibleDebtRepurchaseCosts	294000
CY2018	anip	Payments Of Debt Issuance Costs And Convertible Debt Repurchase Costs PaymentsOfDebtIssuanceCostsAndConvertibleDebtRepurchaseCosts	1572000
CY2017	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	75000000
CY2016	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0
CY2018	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0
CY2017	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	353000
CY2016	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1570000
CY2018	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2978000
CY2017	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0
CY2016	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	2500000
CY2018	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0
CY2017	anip	Payment For Treasury Stock Purchases For Restricted Stock Vestings And Forfeitures PaymentForTreasuryStockPurchasesForRestrictedStockVestingsAndForfeitures	259000
CY2016	anip	Payment For Treasury Stock Purchases For Restricted Stock Vestings And Forfeitures PaymentForTreasuryStockPurchasesForRestrictedStockVestingsAndForfeitures	122000
CY2018	anip	Payment For Treasury Stock Purchases For Restricted Stock Vestings And Forfeitures PaymentForTreasuryStockPurchasesForRestrictedStockVestingsAndForfeitures	659000
CY2017	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	72357000
CY2016	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-729000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-27816000
CY2017	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	3783000
CY2016	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-122317000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	11879000
CY2016Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32367000
CY2015Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	154684000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	36150000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	48029000
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27365000
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	154684000
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	5002000
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	0
CY2017	us-gaap	Interest Paid Net InterestPaidNet	3759000
CY2016	us-gaap	Interest Paid Net InterestPaidNet	4078000
CY2018	us-gaap	Interest Paid Net InterestPaidNet	6285000
CY2017	us-gaap	Income Taxes Paid IncomeTaxesPaid	17786000
CY2016	us-gaap	Income Taxes Paid IncomeTaxesPaid	9537000
CY2018	us-gaap	Income Taxes Paid IncomeTaxesPaid	6397000
CY2017	anip	Accrued Royalties Related To Asset Purchase AccruedRoyaltiesRelatedToAssetPurchase	0
CY2016	anip	Accrued Royalties Related To Asset Purchase AccruedRoyaltiesRelatedToAssetPurchase	3882000
CY2018	anip	Accrued Royalties Related To Asset Purchase AccruedRoyaltiesRelatedToAssetPurchase	0
CY2017	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	485000
CY2016	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	247000
CY2018	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	521000
CY2016Q4	us-gaap	Assets Held For Sale Not Part Of Disposal Group Current AssetsHeldForSaleNotPartOfDisposalGroupCurrent	900000
CY2018	anip	Fair Values Inputs Discount Rate FairValuesInputsDiscountRate	0.15
CY2018	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	1200000
CY2017	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	600000
CY2016	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	1000000
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	63000
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	42.72
CY2015	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y2M12D
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	38000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	40.59
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	30000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	33.89
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	8000
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	46.05
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	63000
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	45.72
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y2M12D
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	50000
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	49.51
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	28000
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	44.49
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	0
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	85000
CY2017Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	48.34
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y7M6D
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	65000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	58.11
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod	33000
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	47.34
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	0
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	0
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	117000
CY2018Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	54.04
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms	P2Y1M6D
CY2018Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	0
CY2017Q4	us-gaap	Convertible Debt Noncurrent ConvertibleDebtNoncurrent	128208000
CY2018Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	11488000
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4006000
CY2018Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	64842000
CY2018Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1666667
CY2018Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2017Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2017Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1666667
CY2017Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2018Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2017Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2018Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	11179
CY2017Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	5203
CY2018Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	112463000
CY2017Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	0
CY2018Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	496000
CY2017Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0
CY2018Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-379000
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0
CY2018	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax	-379000
CY2017	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax	0
CY2016	us-gaap	Other Comprehensive Income Loss Derivatives Qualifying As Hedges Net Of Tax OtherComprehensiveIncomeLossDerivativesQualifyingAsHedgesNetOfTax	0
CY2018	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	-379000
CY2017	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0
CY2016	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	0
CY2018	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	15115000
CY2017	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1076000
CY2016	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	3934000
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	160082000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	15494000
CY2017	us-gaap	Net Income Loss NetIncomeLoss	-1076000
CY2016	us-gaap	Net Income Loss NetIncomeLoss	3934000
CY2018	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1335000
CY2017	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0
CY2016	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	0
CY2018	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	16467000
CY2017	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0
CY2016	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0
CY2018	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	2813000
CY2017	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	0
CY2016	us-gaap	Repayments Of Other Long Term Debt RepaymentsOfOtherLongTermDebt	0
CY2018	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Organization and Business</div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.25in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">ANI Pharmaceuticals, Inc. and its consolidated subsidiaries, ANIP Acquisition Company and ANI Pharmaceuticals Canada Inc. (together, “ANI,” the “Company,” “we,” “us,” or “our”) is an integrated specialty pharmaceutical company focused on delivering value to our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. ANI was organized as a Delaware corporation in April 2001. At our three facilities, of which two are located in Baudette, Minnesota and one is located in Oakville, Ontario, we manufacture oral solid dose products, as well as semi-solids, liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. We also perform contract manufacturing for other pharmaceutical companies.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.31in; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.25in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On June 19, 2013, BioSante Pharmaceuticals, Inc. (“BioSante”) acquired ANIP Acquisition Company (“ANIP”) in an all-stock, tax-free reorganization (the “Merger”), in which ANIP became a wholly-owned subsidiary of BioSante. BioSante was renamed ANI Pharmaceuticals, Inc. The Merger was accounted for as a reverse acquisition pursuant to which ANIP was considered the acquiring entity for accounting purposes.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.25in; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.31in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">On August 6, 2018, our subsidiary, ANI Pharmaceuticals Canada Inc. (“ANI Canada”), acquired all the issued and outstanding equity interests of WellSpring Pharma Services Inc. (“WellSpring”), a Canadian company that performs contract development and manufacturing of pharmaceutical products for a purchase price of $18.0 million, subject to certain customary adjustments. Pursuant to these customary adjustments, the total purchase consideration was $16.7 million. The consideration was paid entirely from cash on hand. In conjunction with the transaction, we acquired WellSpring’s pharmaceutical manufacturing facility, laboratory, and offices, its current book of commercial business, as well as an organized workforce. Following the consummation of the transaction, WellSpring was merged into ANI Canada with the resulting entity’s name being ANI Pharmaceuticals Canada Inc.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.31in; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.25in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Our operations are subject to certain risks and uncertainties including, among others, current and potential competitors with greater resources, dependence on significant customers, and possible fluctuations in financial results. The accompanying consolidated financial statements have been prepared assuming that we will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business. The propriety of using the going-concern basis is dependent upon, among other things, the achievement of future profitable operations, the ability to generate sufficient cash from operations, and potential other funding sources, including cash on hand, to meet our obligations as they become due. We believe the going-concern basis is appropriate for the accompanying consolidated financial statements based on our current operating plan and business strategy for the 12 months following the issuance of this report.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Use of Estimates </div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; margin-bottom: 0px; margin-top: 0px; text-indent: 0.25in; margin-right: 0px; font-size: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">The preparation of financial statements in conformity with U.S. GAAP requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. In the accompanying consolidated financial statements, estimates are used for, but not limited to, stock-based compensation, revenue recognition, allowance for doubtful accounts, variable consideration determined based on accruals for chargebacks, administrative fees and rebates, government rebates, returns and other allowances, allowance for inventory obsolescence, valuation of financial instruments and intangible assets, accruals for contingent liabilities, fair value of long-lived assets, income tax provision, deferred taxes and valuation allowance, purchase price allocations, and the depreciable lives of long-lived assets. Because of the uncertainties inherent in such estimates, actual results may differ from those estimates. Management periodically evaluates estimates used in the preparation of the financial statements for reasonableness.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Credit Concentration </div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.25in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">Our customers are primarily wholesale distributors, chain drug stores, group purchasing organizations, and other pharmaceutical companies.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.25in; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; margin-bottom: 0px; margin-top: 0px; text-indent: 0.25in; margin-right: 0px; font-size: 10pt;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">During the year ended December 31, 2018, </div><div style="background: rgb(255, 255, 0); font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">three </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">customers represented approximately </div></div><div style="background: rgb(255, 255, 0); font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">21</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">%, </div></div><div style="background: rgb(255, 255, 0); font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">23</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">%, and </div></div><div style="background: rgb(255, 255, 0); font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">33</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">% of net revenues, respectively. As of December </div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">31</div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">, </div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">2018</div><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">, accounts receivable from these customers totaled </div></div><div style="background: rgb(255, 255, 0); font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">81</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="background-color: rgb(255, 255, 255); letter-spacing: 0px; top: 0px;;display:inline;">% </div>of net accounts receivable. During the year ended December 31, 2017, three customers represented approximately 29%, 29%, and 20% of net revenues, respectively. During the year ended December 31, 2016, three customers represented approximately 28%, 22%, and 18% of net revenues, respectively.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018Q1	us-gaap	Revenues Revenues	46483000
CY2018Q2	us-gaap	Revenues Revenues	47268000
CY2018Q3	us-gaap	Revenues Revenues	50703000
CY2018Q4	us-gaap	Revenues Revenues	57122000
CY2018Q1	us-gaap	Costs And Expenses CostsAndExpenses	39946000
CY2018Q2	us-gaap	Costs And Expenses CostsAndExpenses	40005000
CY2018Q3	us-gaap	Costs And Expenses CostsAndExpenses	40589000
CY2018Q4	us-gaap	Costs And Expenses CostsAndExpenses	45677000
CY2018Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	6537000
CY2018Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	7263000
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	10114000
CY2018Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	11445000
CY2018Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-592000
CY2018Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-726000
CY2018Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1329000
CY2018Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1910000
CY2018Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	2250000
CY2018Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	2777000
CY2018Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	5037000
CY2018Q4	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	5430000
CY2017Q1	us-gaap	Revenues Revenues	36628000
CY2017Q2	us-gaap	Revenues Revenues	44764000
CY2017Q3	us-gaap	Revenues Revenues	48164000
CY2017Q4	us-gaap	Revenues Revenues	47286000
CY2017Q1	us-gaap	Costs And Expenses CostsAndExpenses	32003000
CY2017Q2	us-gaap	Costs And Expenses CostsAndExpenses	37770000
CY2017Q3	us-gaap	Costs And Expenses CostsAndExpenses	38833000
CY2017Q4	us-gaap	Costs And Expenses CostsAndExpenses	39907000
CY2017	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0
CY2016	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	0
CY2018	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	375000
CY2017Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	4625000
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	6994000
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	9331000
CY2017Q4	us-gaap	Operating Income Loss OperatingIncomeLoss	7379000
CY2017Q1	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-523000
CY2017Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1269000
CY2017Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1654000
CY2017Q4	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-13979000
CY2017Q1	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	1152000
CY2017Q2	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	2681000
CY2017Q3	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	4720000
CY2017Q4	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-9629000
CY2018	anip	Adjustments To Additional Paid In Capital Repurchase Of Convertible Notes And Unwind Of Call Option Overlay AdjustmentsToAdditionalPaidInCapitalRepurchaseOfConvertibleNotesAndUnwindOfCallOptionOverlay	-1709000
CY2018	us-gaap	Repayments Of Convertible Debt RepaymentsOfConvertibleDebt	26125000
CY2017	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	0
CY2016	us-gaap	Proceeds From Derivative Instrument Financing Activities ProceedsFromDerivativeInstrumentFinancingActivities	0
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	201576000
CY2017	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	176842000
CY2016	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	128622000
CY2018Q3	anip	Business Combination Purchase Price Before Adjustments BusinessCombinationPurchasePriceBeforeAdjustments	18000000
CY2018Q3	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	16700000
CY2018Q4	us-gaap	Contract With Customer Asset Net ContractWithCustomerAssetNet	100000
CY2018	anip	Percentage Of Royalties On Net Sales Of Unapproved Products PercentageOfRoyaltiesOnNetSalesOfUnapprovedProducts	less than 1%
CY2017	anip	Percentage Of Royalties On Net Sales Of Unapproved Products PercentageOfRoyaltiesOnNetSalesOfUnapprovedProducts	less than 1%
CY2016	anip	Percentage Of Royalties On Net Sales Of Unapproved Products PercentageOfRoyaltiesOnNetSalesOfUnapprovedProducts	less than 1%
CY2018Q4	anip	Fdic Guaranteed Amount FdicGuaranteedAmount	250000
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	7985000
CY2017	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	13175000
CY2016	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	11717000
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1751000
CY2017	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	690000
CY2016	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1321000
CY2018	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2017	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2016	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	9736000
CY2017	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	13865000
CY2016	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	13038000
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-4630000
CY2017	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	4065000
CY2016	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-8387000
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-556000
CY2017	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-556000
CY2016	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-658000
CY2018	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	-214000
CY2017	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2016	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-5400000
CY2017	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	3509000
CY2016	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-9045000
CY2018	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-221000
CY2017	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-51000
CY2016	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	-134000
CY2018	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	0
CY2017	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	0
CY2016	us-gaap	Excess Tax Benefit From Share Based Compensation Financing Activities ExcessTaxBenefitFromShareBasedCompensationFinancingActivities	617000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4557000
CY2017	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	17425000
CY2016	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4744000
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities	0.088
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities	0.144
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.265
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	0.016
CY2018	anip	Effective Income Tax Rate Reconciliation Share Based Compensation Cost No Windfall Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationCostNoWindfallTaxBenefitPercent	-0.007
CY2017	anip	Effective Income Tax Rate Reconciliation Share Based Compensation Cost No Windfall Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationCostNoWindfallTaxBenefitPercent	0.010
CY2016	anip	Effective Income Tax Rate Reconciliation Share Based Compensation Cost No Windfall Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationCostNoWindfallTaxBenefitPercent	0.057
CY2018	anip	Effective Income Tax Rate Reconciliation Share Based Compensation Cost With Windfall Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationCostWithWindfallTaxBenefitPercent	-0.011
CY2017	anip	Effective Income Tax Rate Reconciliation Share Based Compensation Cost With Windfall Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationCostWithWindfallTaxBenefitPercent	-0.002
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2017	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2016	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.350
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.024
CY2017	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.020
CY2016	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.021
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0.265
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0.819
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate	0
CY2018	anip	Effective Income Tax Rate Reconciliation Nondeductible Expense Foreign Expenses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseForeignExpenses	0
CY2017	anip	Effective Income Tax Rate Reconciliation Nondeductible Expense Foreign Expenses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseForeignExpenses	0
CY2016	anip	Effective Income Tax Rate Reconciliation Nondeductible Expense Foreign Expenses EffectiveIncomeTaxRateReconciliationNondeductibleExpenseForeignExpenses	0.233
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Deductions Qualified Production Activities EffectiveIncomeTaxRateReconciliationDeductionsQualifiedProductionActivities	0
CY2016	anip	Effective Income Tax Rate Reconciliation Share Based Compensation Cost With Windfall Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationCostWithWindfallTaxBenefitPercent	0
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0
CY2017	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.043
CY2016	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	0.014
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.216
CY2017	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	1.066
CY2016	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.547
CY2018Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.19
CY2018Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.24
CY2018Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.43
CY2018Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.46
CY2018Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.19
CY2018Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.23
CY2018Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.42
CY2018Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.46
CY2017Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.10
CY2017Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.23
CY2017Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.41
CY2017Q4	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.83
CY2017Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.10
CY2018Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	1228000
CY2017Q4	us-gaap	Deferred Tax Assets Inventory DeferredTaxAssetsInventory	857000
CY2018Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	9393000
CY2017Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	6355000
CY2018Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5604000
CY2017Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	3029000
CY2017Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.23
CY2017Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.40
CY2017Q4	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.83
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	7748000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	5254000
CY2018Q4	us-gaap	Deferred Tax Assets Hedging Transactions DeferredTaxAssetsHedgingTransactions	3019000
CY2017Q4	us-gaap	Deferred Tax Assets Hedging Transactions DeferredTaxAssetsHedgingTransactions	5617000
CY2018Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	7132000
CY2017Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Returns And Allowances DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReturnsAndAllowances	4927000
CY2018Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4682000
CY2017Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	3030000
CY2018Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	38806000
CY2017Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	29069000
CY2018Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	4437000
CY2017Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	1110000
CY2018Q4	anip	Deferred Tax Liabilities Debt Discount DeferredTaxLiabilitiesDebtDiscount	1316000
CY2017Q4	anip	Deferred Tax Liabilities Debt Discount DeferredTaxLiabilitiesDebtDiscount	3256000
CY2018Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	11000
CY2017Q4	us-gaap	Deferred Tax Liabilities Goodwill And Intangible Assets Intangible Assets DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets	11000
CY2018Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	2813000
CY2017Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	1699000
CY2018Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	8577000
CY2017Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	6076000
CY2018Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2265000
CY2017Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	326000
CY2018Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	27964000
CY2017Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	22667000
CY2018	us-gaap	Operating Loss Carryforwards Limitations On Use OperatingLossCarryforwardsLimitationsOnUse	approximately $0.8 million per year.
CY2017	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	13400000
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2017	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2018	anip	Acquired Finitelived Intangible Asset Amortization Description AcquiredFinitelivedIntangibleAssetAmortizationDescription	we are amortizing 80% of the value of the intangible assets over the first five years of useful lives of the assets and amortizing the remaining 20% of the value of the intangible assets over the second five years of useful lives of the assets.
CY2018Q4	us-gaap	Debt Instrument Repurchase Amount DebtInstrumentRepurchaseAmount	25000000
CY2016Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0
CY2018	us-gaap	Goodwill Period Increase Decrease GoodwillPeriodIncreaseDecrease	600000
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	169648000
CY2018	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	208213000
CY2017	us-gaap	Business Acquisitions Pro Forma Revenue BusinessAcquisitionsProFormaRevenue	188758000
CY2018	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	13287000
CY2017	us-gaap	Business Acquisitions Pro Forma Net Income Loss BusinessAcquisitionsProFormaNetIncomeLoss	-3102000
CY2018Q4	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2019-12-01
CY2018Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	12100000
CY2016Q4	us-gaap	Goodwill Goodwill	1838000
CY2018	us-gaap	Gain Loss On Repurchase Of Debt Instrument GainLossOnRepurchaseOfDebtInstrument	-468000
CY2017	us-gaap	Gain Loss On Repurchase Of Debt Instrument GainLossOnRepurchaseOfDebtInstrument	0
CY2016	us-gaap	Gain Loss On Repurchase Of Debt Instrument GainLossOnRepurchaseOfDebtInstrument	0
CY2018	us-gaap	Derivatives Methods Of Accounting Hedging Derivatives DerivativesMethodsOfAccountingHedgingDerivatives	<div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Hedge Accounting </div></div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.25in; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.25in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">As of January 1, 2018, we adopted guidance intended to simplify hedge accounting by better aligning how an entity’s risk management activities and hedging relationships are presented in its financial statements. The guidance also simplified the application of hedge accounting guidance in certain situations. The adoption of this guidance did not have a material impact on our consolidated financial statements. However, the adoption of this guidance did impact how we accounted for the interest rate swaps we entered into in April 2018 and December 2018. See Note 4 for further details regarding the interest rate swap.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; margin-right: 0px; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.25in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">We use derivative financial instruments to hedge our exposure to interest rate risks. All derivative financial instruments are recognized as either assets or liabilities at fair value on the consolidated balance sheet and are classified as current or long-term based on the scheduled maturity of the instrument.</div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin: 0px 0px 0px 0.25in; background: none;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); background: none; text-decoration: none; letter-spacing: 0px; top: 0px;;display:inline;"> </div></div><div style="font-family: "times new roman", times, serif; font-size: 10pt; margin-bottom: 0px; margin-top: 0px; text-indent: 0.25in; margin-right: 0px;"><div style="font-family: "times new roman", times, serif; font-size: 10pt; color: rgb(0, 0, 0); letter-spacing: 0px; top: 0px;;display:inline;">When we enter into a hedge arrangement and intend to apply hedge accounting, we formally document the hedge relationship and designate the instrument for financial reporting purposes as a fair value hedge, a cash flow hedge, or a net investment hedge. When we determine that a derivative financial instrument qualifies as a cash flow hedge and is effective, the changes in fair value of the instrument are recorded in accumulated other comprehensive income/(loss), net of tax in our consolidated balance sheets and will be reclassified to earnings when the hedged item affects earnings.</div></div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2018	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	1742000
CY2017	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	0
CY2018	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	659000
CY2018	anip	Examination By Taxing Jurisdictions Term ExaminationByTaxingJurisdictionsTerm	P4Y
CY2018	anip	Net Working Capital Adjustment NetWorkingCapitalAdjustment	600000
CY2018	anip	Adjustments To Additional Paid In Capital Repurchase Of Convertible Notes And Unwinding Of Call Option Overlay Net AdjustmentsToAdditionalPaidInCapitalRepurchaseOfConvertibleNotesAndUnwindingOfCallOptionOverlayNet	1700000
CY2018Q4	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.078
CY2017Q4	us-gaap	Debt Instrument Interest Rate Effective Percentage DebtInstrumentInterestRateEffectivePercentage	0.079
CY2018Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	711000
CY2017Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	0
CY2018	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2017	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2016	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0

Files In Submission

Name	View Source	Status
0001144204-19-010541-index-headers.html	Edgar Link	pending
0001144204-19-010541-index.html	Edgar Link	pending
0001144204-19-010541.txt	Edgar Link	pending
0001144204-19-010541-xbrl.zip	Edgar Link	pending
anip-20181231.xml	Edgar Link	completed
anip-20181231.xsd	Edgar Link	pending
anip-20181231_cal.xml	Edgar Link	unprocessable
anip-20181231_def.xml	Edgar Link	unprocessable
anip-20181231_lab.xml	Edgar Link	unprocessable
anip-20181231_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tv512330_10k.htm	Edgar Link	pending
tv512330_ex10-22.htm	Edgar Link	pending
tv512330_ex10-22img01.jpg	Edgar Link	pending
tv512330_ex21.htm	Edgar Link	pending
tv512330_ex23-1.htm	Edgar Link	pending
tv512330_ex31-1.htm	Edgar Link	pending
tv512330_ex31-2.htm	Edgar Link	pending
tv512330_ex32-1.htm	Edgar Link	pending
tv512330_img1.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ANIP
ANI Pharmaceuticals Inc Stock $anip

2018 Q4 Form 10-K Financial Statement

#000114420419010541 Filed on February 27, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIP ANI Pharmaceuticals Inc Stock $anip

2018 Q4 Form 10-K Financial Statement

#000114420419010541 Filed on February 27, 2019

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIP
ANI Pharmaceuticals Inc Stock $anip